Cebranopadol

Cebranopadol (GRT-6005, PRK-101, TRN-228) is a first-in-class small-molecule analgesic that acts as a high-affinity agonist at the nociceptin/orphanin FQ peptide (NOP) receptor and at the three classical opioid receptor subtypes (mu, kappa, and delta), with near-equipotent activation of the NOP and mu-opioid receptors at low-nanomolar concentrations. The compound was discovered at Grunenthal GmbH in Aachen, Germany, and first described in patent literature in 2002. Scientific characterization beginning in 2013 established cebranopadol as a spiro[cyclohexane-dihydropyrano[3,4-b]indole] derivative with binding affinities (Ki) of 0.7 nM at the human mu-opioid receptor, 0.9 nM at the human NOP receptor, 2.6 nM at the kappa-opioid receptor, and 18 nM at the delta-opioid receptor, and with functional potencies (EC50) of 1.2 nM (mu), 13 nM (NOP), 17 nM (kappa), and 110 nM (delta) in calcium mobilization assays, yielding a rank order of potency mu approximately equal to NOP, then kappa, then delta. The compound acts as a full agonist at the mu-opioid and delta-opioid receptors, a near-full agonist at the NOP receptor (89 percent relative efficacy), and a partial agonist at the kappa-opioid receptor (67 percent relative efficacy). A distinctive signaling feature is G-protein bias at the NOP receptor, where cebranopadol promotes G-protein coupling without measurable beta-arrestin 2 recruitment, while retaining full beta-arrestin 2 coupling at the mu-opioid receptor.

The dual NOP and opioid receptor agonism produces a pharmacological profile that is differentiated from conventional mu-selective opioid analgesics in three respects: (1) enhanced relative potency in models of chronic neuropathic and inflammatory pain compared with acute nociceptive pain, with a seven-fold potency advantage in the mouse formalin test relative to the tail-withdrawal paradigm; (2) attenuation of opioid-type respiratory depression, with preclinical evidence of a ceiling effect on respiratory suppression attributable to the NOP receptor contribution; and (3) reduced abuse liability, demonstrated in a Phase 1 human abuse potential study showing less drug-liking and lower subjective effects relative to hydromorphone in non-dependent recreational opioid users, and in a separate study showing less abuse potential than tramadol and oxycodone. Additionally, preclinical studies demonstrated delayed analgesic tolerance development (26 days in cebranopadol-treated animals versus 11 days for morphine at equianalgesic doses in the chronic constriction injury model).

Pharmacokinetics in humans are characterized by complete oral absorption with approximately 40 percent bioavailability reflecting first-pass hepatic metabolism, a late time to maximum plasma concentration (4 to 6 hours), a long terminal elimination half-life of 62 to 96 hours, and an operational half-life of approximately 24 hours supporting once-daily dosing. Steady-state plasma concentrations are achieved after approximately two weeks of daily administration, with an accumulation factor of approximately 2-fold and low peak-trough fluctuation (70 to 80 percent). Clearance is influenced by CYP2C9 phenotype, with poor and intermediate metabolizers showing reduced clearance relative to extensive metabolizers. The compound does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4/5 at concentrations up to 250 nM, indicating a low potential for metabolic drug-drug interactions.

Clinical development has encompassed more than 32 clinical trials involving more than 2,200 participants. A Phase 2 randomized, double-blind, placebo-controlled and active-controlled (tapentadol) trial in chronic low back pain (Christoph et al. 2017) demonstrated statistically significant and clinically relevant analgesic efficacy at doses of 200, 400, and 600 micrograms once daily over 14 weeks. A Phase 2a trial in postoperative acute pain demonstrated efficacy at 400 and 600 microgram doses. Two pivotal Phase 3 trials (ALLEVIATE-1, in post-abdominoplasty pain, and ALLEVIATE-2, in post-bunionectomy pain) met their primary efficacy endpoints, with cebranopadol 400 micrograms demonstrating significant reduction in pain intensity versus placebo. The ALLEVIATE-2 trial additionally showed that a higher proportion of cebranopadol-treated patients required no opioid rescue medication compared with placebo. Tris Pharma, which acquired worldwide rights to cebranopadol through its 2021 acquisition of Park Therapeutics, has announced plans for FDA submission. The compound is not yet approved by any regulatory authority and is not a scheduled controlled substance as of 2025. This monograph reviews the chemistry, synthesis, dual-receptor pharmacology, pharmacokinetics, preclinical and clinical evidence, sourcing, handling, stack interactions, safety profile, and a comparative assessment of five analgesic candidates against cebranopadol on five competency standards.